One half of J&J’s treatment is Lazcluze, a pill that, like Astra’s Tagrisso, blocks a cancer-associated protein called EGFR.

Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

THE return of the sunshine has brought with it an unwelcome pest as deadly processionary caterpillars have been spotted in ...

Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to ...